376 related articles for article (PubMed ID: 15988846)
1. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
Daemmrich A; Krucken G
Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
[No Abstract] [Full Text] [Related]
2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
3. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
4. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
5. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
Lovell MC
Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
[No Abstract] [Full Text] [Related]
6. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
Dunbar MM
Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
[No Abstract] [Full Text] [Related]
7. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
Schwarz S; Frölich L; Striebel JP; Hennerici MG
Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
[No Abstract] [Full Text] [Related]
8. Fumes from the spleen.
Paediatr Perinat Epidemiol; 1991 Jul; 5(3):258-60. PubMed ID: 1881836
[No Abstract] [Full Text] [Related]
9. Women in clinical trials: concluding remarks.
Buc NL
Food Drug Law J; 1993; 48(2):223-6. PubMed ID: 11653146
[No Abstract] [Full Text] [Related]
10. DdI approval offers second chance.
Albert SG
Am Pharm; 1991 Dec; NS31(12):6. PubMed ID: 1763779
[No Abstract] [Full Text] [Related]
11. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
12. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
13. RU-486: legal and policy issues confronting the Food and Drug Administration.
Muhl C
J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
[TBL] [Abstract][Full Text] [Related]
14. Equitable access to biomedical advances: getting beyond the rights impasse.
Mariner WK
Conn Law Rev; 1989; 21(3):571-603. PubMed ID: 11650430
[No Abstract] [Full Text] [Related]
15. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
16. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
17. EU law mandates drug testing in children.
Sinha G
J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
[No Abstract] [Full Text] [Related]
18. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
McKee AE; Farrell AT; Pazdur R; Woodcock J
Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
[TBL] [Abstract][Full Text] [Related]
19. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
20. FDA approves AIDS drug.
Am Pharm; 1992 Sep; NS32(9):13-4. PubMed ID: 1332462
[No Abstract] [Full Text] [Related]
[Next] [New Search]